$InMed Pharmaceuticals (INM.US)$
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
InMed Pharmaceuticals (NASDAQ: INM) has announced the selection of an intravitreal (IVT) formulation for INM-089as a drug candidate for treating dry age-related macular degeneration (AMD). The company has achieved successful delivery of the formulation at doses up to 10 times the projected therapeutic level, demonstrating a favorable pharmacokinetic profil...

$Palantir (PLTR.US)$  
$Foremost Lithium Resource & Technology (FMST.US)$ TOP WL Mon $Banzai International (BNZI.US)$ Act-on-Software Acquisition $NANO Nuclear Energy (NNE.US)$ Top Nuclear Sector $SoundHound AI (SOUN.US)$ Top 2025 AI dont get left wishing you bought low $N2OFF (NITO.US)$ more news coming over 2.00 soon $ImmunityBio (IBRX.US)$ Top Bio “Anktiva” will be a LEADER get on board SOON $ChargePoint (CHPT.US)$ I am hearing “buyout” rumors $Greenwave Technology Solutions (GWAV.US)$ Virginia ...

$InMed Pharmaceuticals (INM.US)$
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
InMed Pharmaceuticals (NASDAQ: INM)has been granted its first international Patent Cooperation Treaty (PCT) patent in Mexico for novel cannabinoid analog compounds. The patent, titled 'Cannabinoid analogs and methods for their preparation', has a 20-year term and covers therapeutic applications for pain, glaucoma, inflammatory disease, anxiety, and neurological conditionsincluding Parkinson...

Here are the areas to watch today after the large move up.
$InMed Pharmaceuticals (INM.US)$  

$EON Resources (EONR.US)$ $Trio Petroleum (TPET.US)$ $Asset Entities (ASST.US)$ $InMed Pharmaceuticals (INM.US)$ $Helius Medical Technologies (HSDT.US)$
📊⚡️📊

$InMed Pharmaceuticals (INM.US)$
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study
InMed Pharmaceuticals (NASDAQ: INM) has announced positive results from a long-term preclinical Alzheimer's Disease study of INM-901. The drug candidate demonstrated significant reductions in several neuroinflammation markers:
- Dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines (TNF...

$InMed Pharmaceuticals (INM.US)$ InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study
newsfile· 2 mins ago
INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's
Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')
mRNA profile showed a reduction of several key neuroinflammatory genes in the brain

$InMed Pharmaceuticals (INM.US)$
InMed Enters Into Standby Equity Purchase Agreement
InMed Pharmaceuticals (NASDAQ: INM) has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, , managed by Yorkville Advisors Global LP, on December 13, 2024. The agreement allows InMed to sell up to $10 million of common shares over a 36-month period.
The shares will be priced at 97% of the Market Price during a specified three-day pricing period. The total shares issuable are to 19.99% of...

$InMed Pharmaceuticals (INM.US)$  this stock needs volume